These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 37247937)

  • 1. The Suppressive Effect of Rebastinib on Triple-negative Breast Cancer Tumors Involves Multiple Mechanisms of Action.
    Feng K; Jian C; Xiao H; Jiang H; Yang J; Yang M; Sun A; Song W; Chestkov AV; Vasilevich NI; Sun L
    Anticancer Res; 2023 Jun; 43(6):2609-2624. PubMed ID: 37247937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDK16 promotes the progression and metastasis of triple-negative breast cancer by phosphorylating PRC1.
    Li X; Li J; Xu L; Wei W; Cheng A; Zhang L; Zhang M; Wu G; Cai C
    J Exp Clin Cancer Res; 2022 Apr; 41(1):149. PubMed ID: 35449080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2
    Harney AS; Karagiannis GS; Pignatelli J; Smith BD; Kadioglu E; Wise SC; Hood MM; Kaufman MD; Leary CB; Lu WP; Al-Ani G; Chen X; Entenberg D; Oktay MH; Wang Y; Chun L; De Palma M; Jones JG; Flynn DL; Condeelis JS
    Mol Cancer Ther; 2017 Nov; 16(11):2486-2501. PubMed ID: 28838996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Penta-O-galloyl-beta-D-glucose induces G1 arrest and DNA replicative S-phase arrest independently of cyclin-dependent kinase inhibitor 1A, cyclin-dependent kinase inhibitor 1B and P53 in human breast cancer cells and is orally active against triple negative xenograft growth.
    Chai Y; Lee HJ; Shaik AA; Nkhata K; Xing C; Zhang J; Jeong SJ; Kim SH; Lu J
    Breast Cancer Res; 2010; 12(5):R67. PubMed ID: 20809980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ginsenoside Rk1 induces cell cycle arrest and apoptosis in MDA-MB-231 triple negative breast cancer cells.
    Hong Y; Fan D
    Toxicology; 2019 Apr; 418():22-31. PubMed ID: 30797898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling.
    Ji X; Meng X; He Q; Xiang X; Shi Y; Zhu X
    Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chloroform Fraction of Methanolic Extract of Seeds of Annona muricata Induce S Phase Arrest and ROS Dependent Caspase Activated Mitochondria-Mediated Apoptosis in Triple-Negative Breast Cancer.
    Kariyil BJ; Ayyappan UPT; Gopalakrishnan A; George AJ
    Anticancer Agents Med Chem; 2021; 21(10):1250-1265. PubMed ID: 32951586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression.
    Anbalagan M; Sheng M; Fleischer B; Zhang Y; Gao Y; Hoang V; Matossian M; Burks HE; Burow ME; Collins-Burow BM; Hangauer D; Rowan BG
    Mol Cancer Res; 2017 Nov; 15(11):1491-1502. PubMed ID: 28751463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
    Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
    Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor Effect of KX-01 through Inhibiting Src Family Kinases and Mitosis.
    Kim S; Min A; Lee KH; Yang Y; Kim TY; Lim JM; Park SJ; Nam HJ; Kim JE; Song SH; Han SW; Oh DY; Kim JH; Kim TY; Hangauer D; Lau JY; Im K; Lee DS; Bang YJ; Im SA
    Cancer Res Treat; 2017 Jul; 49(3):643-655. PubMed ID: 27737538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer.
    Xu S; Sun X; Luo L; Yang Y; Guo Q; Tang S; Jiang Z; Li Y; Han J; Gan W; Yang F; Zhang X; Liu Y; Sun C; He J; Liu M; Zuo D; Zhu W; Wu Y
    Biomed Pharmacother; 2022 Nov; 155():113537. PubMed ID: 36113258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
    Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene Expression Alterations Associated with Oleuropein-Induced Antiproliferative Effects and S-Phase Cell Cycle Arrest in Triple-Negative Breast Cancer Cells.
    Messeha SS; Zarmouh NO; Asiri A; Soliman KFA
    Nutrients; 2020 Dec; 12(12):. PubMed ID: 33297339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
    Martin JL; Julovi SM; Lin MZ; de Silva HC; Boyle FM; Baxter RC
    Breast Cancer Res; 2017 Aug; 19(1):90. PubMed ID: 28778177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models.
    Diamond JR; Eckhardt SG; Tan AC; Newton TP; Selby HM; Brunkow KL; Kachaeva MI; Varella-Garcia M; Pitts TM; Bray MR; Fletcher GC; Tentler JJ
    Clin Cancer Res; 2013 Jan; 19(1):291-303. PubMed ID: 23136197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells.
    Salem I; Alsalahi M; Chervoneva I; Aburto LD; Addya S; Ott GR; Ruggeri BA; Cristofanilli M; Fernandez SV
    Breast Cancer Res; 2016 Mar; 18(1):37. PubMed ID: 27009091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells.
    Basu GD; Pathangey LB; Tinder TL; Gendler SJ; Mukherjee P
    Breast Cancer Res; 2005; 7(4):R422-35. PubMed ID: 15987447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
    Greer YE; Gilbert SF; Gril B; Narwal R; Peacock Brooks DL; Tice DA; Steeg PS; Lipkowitz S
    Breast Cancer Res; 2019 Feb; 21(1):27. PubMed ID: 30777098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
    Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
    Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
    Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
    Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.